Fabregas Jesus C, Ramnaraign Brian, George Thomas J
Department of Medicine, Division of Hematology-Oncology, University of Florida Health Cancer Center, University of Florida, Gainesville, FL.
Department of Medicine, Division of Hematology-Oncology, University of Florida Health Cancer Center, University of Florida, Gainesville, FL.
Clin Colorectal Cancer. 2022 Sep;21(3):198-203. doi: 10.1016/j.clcc.2022.05.006. Epub 2022 Jun 3.
Colon cancer needs better screening and treatment options. Its incidence in the young population is rising. Recent changes in guidelines recommend beginning screening for colon cancer at the age of 45. Circulating tumor DNA presents an opportunity to select patients for administration of adjuvant chemotherapy. Immunotherapy is an option for patients with a deficiency in mismatch repair proteins. However, its efficacy outside of this group of patients remains a challenge. Targeted therapies such as BRAF inhibitors are an option for patients with poor prognosis, for whom cytotoxic chemotherapy is not as effective. This review presents the recently published evidence regarding screening and treating patients with colon cancer.
结肠癌需要更好的筛查和治疗方案。其在年轻人群中的发病率正在上升。最近指南的变化建议从45岁开始进行结肠癌筛查。循环肿瘤DNA为选择辅助化疗的患者提供了机会。免疫疗法是错配修复蛋白缺陷患者的一种选择。然而，在这类患者群体之外其疗效仍然是一个挑战。靶向疗法如BRAF抑制剂是预后较差患者的一种选择，对他们来说细胞毒性化疗效果不佳。本综述介绍了最近发表的关于结肠癌患者筛查和治疗的证据。
